BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu S, Oremo JA, Li S, Zhen M, Tang Y, Du Y. Synergistic antitumor activities of docetaxel and octreotide associated with apoptotic-upregulation in castration-resistant prostate cancer. PLoS One 2014;9:e91817. [PMID: 24632829 DOI: 10.1371/journal.pone.0091817] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Gu CY, Dai B, Zhu Y, Lin GW, Wang HK, Ye DW, Qin XJ. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma. Mol Med 2022;28:78. [PMID: 35836112 DOI: 10.1186/s10020-022-00504-6] [Reference Citation Analysis]
2 Safi A, Heidarian E, Ahmadi R. Quercetin Synergistically Enhances the Anticancer Efficacy of Docetaxel through Induction of Apoptosis and Modulation of PI3K/AKT, MAPK/ERK, and JAK/STAT3 Signaling Pathways in MDA-MB-231 Breast Cancer Cell Line. Int J Mol Cell Med 2021;10:11-22. [PMID: 34268250 DOI: 10.22088/IJMCM.BUMS.10.1.11] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
3 He S, Zhang L, Bai S, Yang H, Cui Z, Zhang X, Li Y. Advances of molecularly imprinted polymers (MIP) and the application in drug delivery. European Polymer Journal 2021;143:110179. [DOI: 10.1016/j.eurpolymj.2020.110179] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
4 Jonnalagadda B, Arockiasamy S, Vetrivel U, P A A. In silico docking of phytocompounds to identify potent inhibitors of signaling pathways involved in prostate cancer. J Biomol Struct Dyn 2021;39:5182-208. [PMID: 32643549 DOI: 10.1080/07391102.2020.1785944] [Reference Citation Analysis]
5 Li Z, Jiang X, Chen P, Wu X, Duan A, Qin Y. Combined effects of octreotide and cisplatin on the proliferation of side population cells from anaplastic thyroid cancer cell lines. Oncol Lett 2018;16:4033-42. [PMID: 30128025 DOI: 10.3892/ol.2018.9105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Ishii K, Matsuoka I, Kajiwara S, Sasaki T, Miki M, Kato M, Kanda H, Arima K, Shiraishi T, Sugimura Y. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells. J Cancer Res Clin Oncol 2018;144:89-98. [PMID: 29098395 DOI: 10.1007/s00432-017-2536-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
7 Hormaechea-Agulla D, Jiménez-Vacas JM, Gómez-Gómez E, L-López F, Carrasco-Valiente J, Valero-Rosa J, Moreno MM, Sánchez-Sánchez R, Ortega-Salas R, Gracia-Navarro F, Culler MD, Ibáñez-Costa A, Gahete MD, Requena MJ, Castaño JP, Luque RM. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer. FASEB J 2017;31:4682-96. [PMID: 28705809 DOI: 10.1096/fj.201601264RRR] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 5.6] [Reference Citation Analysis]
8 Sarojini S, Pecora A, Milinovikj N, Barbiere J, Gupta S, Hussain ZM, Tuna M, Jiang J, Adrianzen L, Jun J, Catello L, Sanchez D, Agarwal N, Jeong S, Jin Y, Remache Y, Goy A, Ndlovu A, Ingenito A, Suh KS. A combination of high dose rate (10X FFF/2400 MU/min/10 MV X-rays) and total low dose (0.5 Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytes. Melanoma Res 2015;25:376-89. [PMID: 26177150 DOI: 10.1097/CMR.0000000000000174] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Degirmenci M, Erdogan AP, Bulut G, Atmaca H, Uzunoglu S, Karaca B, Karabulut B, Uslu R. Octreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells. Tumour Biol 2016;37:4939-44. [PMID: 26531719 DOI: 10.1007/s13277-015-4331-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
10 Sharan RN, Vaiphei ST, Nongrum S, Keppen J, Ksoo M. Consensus reference gene(s) for gene expression studies in human cancers: end of the tunnel visible? Cell Oncol (Dordr) 2015;38:419-31. [PMID: 26384826 DOI: 10.1007/s13402-015-0244-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
11 Priftakis D, Kritikos N, Stavrinides S, Kleanthous S, Baziotis N. Neuroendocrine differentiation in castration-resistant prostate cancer: A case report. Mol Clin Oncol 2015;3:1392-4. [PMID: 26807253 DOI: 10.3892/mco.2015.645] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
12 Meli V, Caltagirone C, Falchi AM, Hyde ST, Lippolis V, Monduzzi M, Obiols-Rabasa M, Rosa A, Schmidt J, Talmon Y, Murgia S. Docetaxel-Loaded Fluorescent Liquid-Crystalline Nanoparticles for Cancer Theranostics. Langmuir 2015;31:9566-75. [PMID: 26293620 DOI: 10.1021/acs.langmuir.5b02101] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
13 Karaca B, Degirmenci M, Ozveren A, Atmaca H, Bozkurt E, Karabulut B, Sanli UA, Uslu R. Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines. Cancer Chemother Pharmacol 2015;75:1273-80. [DOI: 10.1007/s00280-015-2756-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]